semaglutide for hfpef Weight loss drug benefits obese patients presenting with HFpEF, type 2 diabetes Semaglutide in HFpEF across obesity

It is not clear whether GLP-1 users lost weight and, if so, how much or achieved diabetes control

Adipocyte-secreted BMP8b mediates adrenergic-induced remodeling of the neuro-vascular network in adipose tissue

Acting on the Brain: It targets appetite centers in the brain to reduce hunger and calorie intake

In older adults with type 2 diabetes mellitus (T2DM), the prevalence of sarcopenia is 23 times higher than in non-diabetic peers.1 This dual burden not only impairs physical performance and quality of life but also increases the risk of falls, frailty, and mortality.2 In recent years, growing concerns have arisen regarding the potential impact of glucose-lowering medications on muscle health, generating significant clinical debate

Levothyroxine malabsorption induced by diabetic gastroparesis exacerbated during pregnancies: effect of intramuscular levothyroxine injections and levothyroxine softgel capsules

Implications of cardiovascular outcome trials with injectable antidiabetic agents